SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LTD. Registered office: JAIPUR HOSPITAL, LAL KOTHI, NEAR SMS STADIUM, TONK

ROAD, JAIPUR - 302015 (Rajasthan) CIN: L85110RJ1989PLC005206

13.11.2020

To,

The Manager,

Corporate Relationship Department,

BSE Ltd.

25th Floor P.J. Towers,

Dalal Street, Fort,

MUMBAI-400 001.

Ref: Scrip Code: - 524548

Sub: - Outcome of Board Meeting held on 13.11.2020 pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Regulations").

Dear Sir/Ma'am,

The Board of Directors of the Company in their meeting held on 13.11.2020 at the registered office of the Company situated at Jaipur Hospital, Near SMS Stadium, Lal Kothi, Tonk Road, Jaipur at 04:00 P.M. to 9:30 P.M. inter alia transacted the following business:

- 1. Approved the Unaudited Financial Results of the Company in compliance with Regulation 33 and took on record the Limited Review Report thereon for the quarter and half year ended on 30.09.2020
- 2. The Board took note of various Compliances for the Quarter and half year ended on 30.09.2020 pertinent to SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take it on record and acknowledge the same.

Thanking You,

For SHARMA EAST INDIA HOSPITALS &

MEDICAL RESEARCH LTD.

Shailendra Kumar Sharma

(Managing Director)

Contact: 0141-2742266 / 2742619

Fax: 0141-2742472

E-mail - sharmaeastindia@gmail.com

Website: www.jaipurhospital.co.in

SHARMA EAST INDIA HOSPITALS AND MEDICAL RESEARCH LTD.

Registered office: JAIPUR HOSPITAL, LAL KOTHI, NEAR SMS STADIUM, TONK ROAD, JAIPUR
- 302015 (Rajasthan)

CIN: L85110RJ1989PLC005206

13.11.2020

To,

The Manager,
Corporate Relationship Department,
BSE Ltd.
25th Floor P.J. Towers,
Dalal Street, Fort,
MUMBAI-400 001.

Ref: Scrip Code: - 524548

Sub: - Submission of Standalone Unaudited Financial Results for the quarter and half year ended on 30.09.2020 under regulation 30 & 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Dear Sir,

Please find enclosed herewith the Standalone Unaudited Financial Results for the quarter and half year ended on 30.09.2020 in compliance of regulation 30 read with 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 duly approved by the Board of Directors of the Company in their meeting held on Friday, 13th November, 2020 alongwith Auditors' Report on Limited Review.

Kindly take it on record and acknowledge the same.

Thanking You,

SHAILENDRA KUMAR SHARMA

Contact: 0141-2742266 / 2742619

For SHARMA EAST INDIA HOSPITAL MEDICAL RESEARCH LIMITED

(Managing Director)

Fax: 0141-2742472

E-mail - sharmaeastindia@gmail.com Website: www.jaipurhospital.co.in

SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED NEAR SMS STADIUM, LAL KOTHI, TONK ROAD **JAIPUR**

CIN: L85110RJ1989PLC005206

Statement of Standalone Unaudited Financial Results for the Quarter/Half Year Ended on September 30, 2020

			Quarter End	led	Half Yea	ar Ended	(Rs. in lakhs Year Ended
S. No.		30.09.2020 (Unaudited)	30.06.2020 (Unaudited)	30.09.2019 (Unaudited)	30.09.2020 (Unaudited)	30.09.2019 (Unaudited)	31.03.2020 (Audited)
1	Income from Operations						
	Revenue from Operations Other Income	249.33	101.88	402.32	351.21	835.24 6.50	1,616.73 3.31
	Total Revenue	249.33	101.88	402.32	351.21	841.74	1,620.04
	Expenses				DOLLAR	011.74	1,020.04
(b)	Cost of materials consumed Purchase of stock in trade	16.08 0.33	5.46 0.02	50.09 • 0.97	21.54 0.35	107.65 2.81	195.14 4.65
(c)	Change in Inventories of stock in trade	0.00	-	(0.02)	- 1	(0.12)	(0.25
(a)	Employee benefits expense	44.30	36.76	68.44	81.06	137.02	305.91
	Finance cost	23.84	20.93	23.11	44.77	64.67	115.39
	Depreciation and amortisation expense Other Expenses	22.88	8.56	10.93	31.44	21.81	42.86
(g)		122.43	67.92	240.28	190.35	490.08	918.63
_	Total Expenses	229.86	139.65	393.80	369.51	823.92	1,582.33
3	Profit/(Loss) before exceptional items & tax (1-2)	19.47	(37.77)	8.52	(18.30)	17,82	37.71
	Exceptional Items	-	-		- '- '	-	07.71
	Profit/(Loss) before tax (3-4)	19.47	(37.77)	8.52	(18.30)	17.82	37.71
6	Tax expense				, , ,	27.02	37.71
	Current tax						
	Taxation for Earlier year	-	-	- 1	-	=	5.88
	Deferred tax	-	-		-	-	(0.03
	Describe the		-	(1.59)	-	-	1.26
7	Profit/(Loss) for the period (5-6)	40.45	(2)	(1.59)	-	-	7.11
8	Other Comprehensive Income	19.47	(37.77)	10.11	(18.30)	17.82	30.60
(i)	Items that will not be reclassified to profit or loss						
(1)	Income tax relating to items that will not be reclassified to	-	-	9.19	-	9.19	9.19
(11)	profit or loss	-	.	(0.95)	-	(0.95)	(0.96)
	Other Comprehensive Income for the period	-	-	8.24	-	8.24	8.23
40	Total Comprehensive Income (7+8)	19.47	(37.77)	18.35	(18.30)	26.06	38.83
	Paid up equity share capital (face value of Rs. 10/- each)	328.38	328.38	328.38	328,38	328.38	328.38
11	Earning per share	1000					
	Basic	0.59	-	0.51	-	0.79	1.18
ote	Diluted	0.59	-	0.51	-	0.79	1.18

- 1. These results have been reviewed by the Audit Committee and taken on record by the Board of Directors at their meeting held on 13.11.2020. Limited Review Report on the above financial results has been received from the Statutory Auditors of the Company. This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules. 2015 (Ind AS) as prescribed under section 133 of the Companies Act. 2013, and other recognized accounting practices and policies to the extent applicable.
- 2. The figures of previous period/year have been re-grouped/re-arranged and / or recast wherever found necessary.

AUTHURISED

The outbreak of COVID 19 pandemic and consequent lockdown has impacted the regular business operations. The results for the quarter are therefore not comparable with those for the previous quarter. The Company has assessed the impact of pandemic on its financial results/position based on the internal and external information available up to the date of approval of these financial results and expects that there will not be material change in the carrying value of its assets. The Company continues to monitor the economic effects of the pandemic while taking steps to improve its execution efficiencies and the financial outcome.

Place: Jaipur

Date: 13.11.2020

For and on behalf of the Board of Directors SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED

> ilendra Kumar Sharma MANAGING DIRECTOR DIN 00432070

SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED NEAR SMS STADIUM, TONK ROAD JAIPUR CIN: L85110RJ1989PLC005206

STATEMENT OF UNAUDITED ASSETS AND LIABILITIES AS AT SEPTEMBER 30, 2020

Particulars	As at 30th	(Rs. in lakhs) As at 31st March
	September 2020	2020
ASSETS		2020
Non-Current Assets		
(a) Property, Plant and Equipment	586.82	440.91
(b)Capital work-in-progress	-	174.30
(c) Financial Assets		174.50
(i) Investments	189.23	189.23
(ii) Others	14.55	14.52
(d) Deferred Tax Assets (Net)	_	11,02
(e) Other Non-Current Assets	21.00	2.20
Total Non- Current Assets	811.60	821.16
Current Assets		
(a) Inventories	61.59	61.59
(b) Financial Assets		
(i) Trade Receivable	475.32	474.89
(ii) Cash and Cash Equivalents	313.72	10.37
(iii) Bank balances other than	5.69	2.19
(ii) above		
(iv) Others	10.84	8.73
(b) Other Current Assets	629.24	606.95
Total Current Assets	1,496.40	1,164.72
T. 114		
Total Assets	2,308.00	1,985.88
EQUITY AND LIABILITIES		
EQUITY		
(a) Equity Share capital	415.75	A1E 7E
(b) Other Equity	393.82	415.75
Total Equity	809.57	412.13 827.88
		027.00
LIABILITIES		
Non-Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	187.56	159.90
(ii) Other Financial Liabilities		103.50
(b) Deferred Tax Liability	17.63	17 (2
(c) Other Non Current Liabilities	34.00	17.63
Total Non - current liabilities	239.19	34.00 211.53
	203.23	211.55
Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	585.87	529.63
(ii) Trade Payables	126.40	157.22
(iii) Other Financial Liabilities	187.32	224.58
(b) Other Current Liabilities	353.77	29.16
(c) Provisions	5.88	5.88
Total Current liabilities	1,259.24	946.47
Tetal Vist West		
Total Liabilities	1,498.43	1,158.00
Total Equity and Liabilities SVII 200	2 200 00	
(AN	2,308.00	1,985.88

ACTHORISEB SIGNATURY

SHARMA EAST INDIA HOSPITALS & MEDICAL RESEARCH LIMITED JAIPUR HOSPITAL, NEAR SMS STADIUM, LAL KOTHI, TONK ROAD JAIPUR, RAJASTHAN

CIN: L85110RJ1989PLC005206

STATEMENT OF CASH FLOWS FOR THE QUARTER & HALF YEAR ENDED ON SEPTEMBER 30, 2020

(Amount in ₹)

	(Amount in ₹)		
PARTICULARS	For the Half year ended September 30, 2020	For the year ended March 31, 2020	
A. Cash Flow from Operating Activities			
The state of the s			
Profit before tax	(18.30)	37.7	
Adjustments to reconcile profit before tax to net cash flows:	(10.30)	37.71	
Depreciation and impairment of property, plant and equipment	31.44	42.86	
(Gain)/Loss on disposal of property, plant and equipment			
Interest income		(0.00)	
Finance costs	44.77	(0.09)	
Incremental Interest	44.//	115.34	
Movements in provisions	-	0.05	
Other adjustments to reconcile profit or loss		(0.74)	
Operating Profit before working capital changes	57.91	405.42	
Working Capital Changes:	37.71	195.13	
Increase/(Decrease) in non current liabilites			
(Increase)/Decrease in trade and other receivables and prepayments	(0.44)	(23.00) (129.77)	
(Increase)/Decrease in other assets & liabilities	(24.44)	(0.57)	
(Increase)/Decrease in other current assets	(22.28)	(29.26)	
(Increase)/Decrease in inventories	-	0.27	
Increase/(Decrease) in other current financial liabilities	(37.26)	66.76	
Increase/(Decrease) in other current liabilities	324.60	(5.82)	
Increase/(Decrease)in trade and other payables	(30.82)	53.35	
Cash Generated from Operations	267.27	127.09	
Income tax paid	-	(5.85)	
Net Cash from Operating Activities (A)	267.27	121.24	
B. Cash Flow from Investing Activities			
Proceeds from sale of property, plant and equipment	-		
Purchase of property, plant and equipment (including Capital Work in		•	
Progress)	(3.05)	(450.03)	
Interest recevied	(3.03)	(150.03) 0.09	
Net Cash used in Investing Activities(B)	(3.05)	(149.94)	
C. Cash Flow from Financing Activities			
Proceeds from / (Repayment of) Short Term Borrowings	56.24	///2 001	
Proceeds from / (Repayment of) Long Term Borrowings		(463.28)	
Interest Paid	27.66	104.13	
Net cash used in Financing Activities (C)	39.13	(115.34) (474.49)	
Net increase/(Decrease) in cash and cash equivalents(A+B+C)	303.35	(503.19)	
Cash and cash equivalents at the basis is a fall			
Cash and cash equivalents at the beginning of the year	10.37	513.56	
Cash and cash equivalents at the end of the year	313.72	10.37	

313.72

313.72

ATTICHISED RESIDENT AND SIGNATORY SEARCH SEARCH SIGNATORY SEARCH SIGNATORY SEARCH SEAR



Amit Goyal & Co. CHARTERED ACCOUNTANTS

A-8, II Floor, Ganpati Enclave, Ajmer Road, JAIPUR - 302 006 Tel.No.: 2225036, 2225065

Fax: 0141-2223211 E-mail: amitgoyalnco@yahoo.com CH 1811112020

Date

UDIN-20075730AAAACT8640

Independent Auditor's Review Report on Unaudited Quarterly and Year to Date Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

To,
The Board of Directors
Sharma East India Hospitals and Medical Research Limited

- 1. We have reviewed the accompanying statement of unaudited financial results ('the Statement') of Sharma East India Hospitals and Medical Research Limited ('the Company') for the quarter ended September 30, 2020 and the year to date results for the period April 01, 2020 to September 30, 2020, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including relevant circulars issued by the SEBI from time to time.
- 2. The Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under Section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 (as amended), including relevant circulars issued by SEBI from time to time. Our responsibility is to express a conclusion on the Statement based on our review.
- 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by

the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under Section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards, prescribed under Section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended), including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR AMIT GOYAL & CO. CHARTERED ACCOUNTANTS

(Rajeev Kumar) PARTNER

Membership No.075

Firm Registration No. 003

730AAAACT8640

Jaipur 13.11.2020